Huma Optogenetics Therapy

 

In a breakthrough study published in Molecular Therapy, researchers from Nanoscope Therapeutics demonstrated that synthetic biology can restore vision in patients with inherited retinal degenerations (IRDs), including retinitis pigmentosa (RP). Using a mutation-independent gene therapy based on a synthetic protein called Multi-Characteristic Opsin (MCO-010), the team was able to restore functional vision in individuals who were legally blind. This work highlights the power of combining protein engineering with gene delivery technologies and shows how synthetic biology is beginning to reshape clinical treatment options for previously untreatable conditions.

The Challenge of Treating Retinal Degeneration

Retinitis pigmentosa (RP) is a genetically complex disease caused by mutations in nearly 200 different genes, leading to the gradual loss of photoreceptor cells. Traditional gene therapies typically target specific genetic mutations and require intact photoreceptors, an approach that fails in advanced RP where these cells have largely degenerated. Moreover, around 40% of RP cases lack a definitive genetic diagnosis or involve multiple mutations. To overcome these challenges, researchers are pursuing mutation-independent strategies that bypass photoreceptors altogether by targeting surviving retinal neurons to restore visual function.

Engineering a Synthetic Opsin for Ambient-Light Vision

To address the limitations of conventional gene therapy, the team engineered MCO-010, a synthetic opsin or “synthopsin” that functions independently of a patient’s mutation profile or photoreceptor status. MCO-010 is composed of three engineered, non-mammalian protein domains: a blue-light-sensitive calcium ion channel from Chlamydomonas reinhardtii, a red-light-responsive ligand from Chlamydomonas noctigama, and mCherry, a fluorescent protein derived from Discosoma anemones that stabilizes the protein structure and enhances function.

Through targeted mutations, MCO-010 was optimized to broaden spectral sensitivity and speed up response kinetics under ambient light. Unlike native opsins, MCO-010 does not depend on chromophore recycling by retinal pigment epithelium (RPE) or Müller cells, making it functional even in severely degenerated retinas.

Targeted and Minimally Invasive Delivery

The gene encoding MCO-010 was packaged into an optimized AAV2 vector (vMCO-010) driven by a humanized mGluR6 promoter, selectively targeting ON-bipolar cells, neurons preserved even in late-stage RP. Targeting bipolar cells preserves upstream visual processing and higher spatial resolution compared to retinal ganglion cells (RGCs).

The AAV2 vector was engineered to cross the inner limiting membrane, allowing for intravitreal injection, a minimally invasive method that enhances retinal coverage and patient accessibility. Additionally, the mCherry domain enables non-invasive monitoring of gene expression through fundus autofluorescence imaging, marking a first in human optogenetic therapy. Optogenetic therapy aims to restore the retina’s ability to detect light by genetically reprogramming surviving inner retinal neurons into light-sensitive cells (photosensitive cells), even after degenerative diseases like retinitis pigmentosa cause the loss of photoreceptor cells (rods and cones).

Safety and Tolerability

Despite MCO-010’s synthetic, non-mammalian origin, the therapy was well-tolerated in the study. No serious adverse events occurred. Mild intraocular inflammation and temporary increases in intraocular pressure were effectively managed with corticosteroids. There were no increases in anti-AAV2 antibody levels post-treatment. Some patients developed cataracts or vitreous haze, which temporarily interfered with imaging, but these events were manageable and did not compromise long-term safety.

Clinical Trial Results: Regaining Vision

In a Phase I/IIa open-label trial, four patients with RP due to ABCA4 mutations received a single intravitreal injection of vMCO-010. Despite severe photoreceptor loss, inner retinal layers remained intact, ideal for targeting bipolar cells.

Over 52 weeks, the following outcomes were observed:

  • Visual Acuity Gains: All patients showed measurable improvement using the Freiburg Visual Acuity Test, especially between weeks 12 and 16.
  • Visual Field Expansion: Two patients exhibited improved visual field indices, correlating with strong mCherry expression in those regions.
  • Functional Vision: In mobility tests under dim lighting, patients navigated obstacles more accurately and quickly. By week 8, all demonstrated 100% accuracy in shape recognition and motion detection tasks.
  • Quality of Life: NEI VFQ-25 survey results revealed improved self-reported visual function and daily independence. Notably, some patients began arriving at follow-ups unassisted, clear evidence of restored mobility and vision.

A Paradigm Shift: Restoring Vision Without Targeting Mutations

What makes this therapy truly revolutionary is its mutation-independent design. Although all participants carried ABCA4 variants, several had additional mutations that would normally exclude them from standard gene therapy trials. MCO-010 bypasses this limitation by targeting the shared outcome, light insensitivity, rather than any specific mutation. This marks a shift in how gene therapies are conceptualized, expanding access to patients with unknown, complex, or multiple mutations who were previously ineligible for treatment.

Future Directions and Challenges

While the results of this pilot study are promising, the researchers acknowledge several limitations and areas for future investigation. The small sample size and open-label design necessitate larger controlled prospective clinical trials with dose escalation to fully characterize efficacy and safety. They also noted that naturally occurring and AAV-related ocular opacities such as corneal keratic precipitates, vitreous haze, and cataract progression can confound important endpoints like visual acuity and visual field testing.

Future studies may need to incorporate options to treat these opacities to optimize assessment of treatment outcomes. Additionally, longer-term follow-up will be important to determine the durability of the treatment effect and whether redosing may be necessary.

The researchers also highlight the potential for high-resolution fluorescence imaging using scanning laser ophthalmoscopy to better correlate gene expression patterns with functional improvements and to monitor potential loss of expression over time.

Reference

Mohanty et al. A synthetic opsin restores vision in patients with severe retinal degeneration. Molecular Therapy (2025). S1525-0016(25)00205-9. DOI: 10.1016/j.ymthe.2025.03.031

 

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217

2.  American Society of Hematology (ASH) Annual Meeting 2024.

Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)